natgillin/translations-raw huggingface dataset:
An equipment according to claim 6, wherein the urea finishing device is a fluid bed granulation unit. 
Oprema sukladno patentnom zahtjevu 6, pri čemu je uređaj za krute čestice uree jedinica za granulaciju s fluidnim ležištem.
An equipment according to claim 6 or 7, wherein a plurality of venturi tubes is present in parallel. 
Oprema sukladno patentnom zahtjevu 6 ili 7, pri čemu je paralelno prisutno više venturi cijevi.
A method according to claim 12, wherein the method comprises installing one or more venturi scrubbers in parallel to the already present venturi scrubber. 
Postupak sukladno patentnom zahtjevu 12, pri čemu taj postupak sadrži postavljanje jednog ili više venturijskih pročistača paralelno s već postojećim venturinskim pročistačem.
A method according to claim 12 or 13, wherein the plant further comprises an acid scrubber for the removal of ammonia, preferably downstream of the dust scrubbing section. 
Postupak sukladno patentnom zahtjevu 12 ili 13, pri čemu postrojenje još sadrži kiseli pročistač za uklanjanje amonijaka, poželjno nizvodno od segmenta za pročišćavanje prašine.
Crystalline Form or composition for use according to claim 11 wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart. 
Kristalni Oblik ili kompozicija za primjenu u skladu sa patentnim zahtjevom 11 gdje tromboembolijski poremećaj je odabran iz grupe koja se sastoji od arterijskih kardiovaskularnih tromboembolijskih poremećaja, venskih kardiovaskularnih tromboembolijskih poremećaja i tromboembolijskih poremećaja u komorama srca.
linked to the carbon atom at position 3 of the pyrrolidine ring is —CH2—ONO2; and R1 linked to the carbon atom at position 4 of the pyrrolidine ring is H; 
vezan na ugljikov atom u položaju 3 pirolidinskog prstena je skupina donor dušikovog monoksida -ONO2; i R1 vezan na ugljikov atom u položaju 4 pirolidinskog prstena je H (ovdje identificirani kao spojevi redom 1b1, 1b2 i 1b3);
linked to the carbon atom at position 3 of the pyrrolidine ring is —ONO2; and R1 linked to the carbon atom at position 4 of the pyrrolidine ring is H; 
vezan na ugljikov atom u položaju 3 pirolidinskog prstena je skupina donor dušikovog monoksida -ONO2; i R1 vezan na ugljikov atom u položaju 4 pirolidinskog prstena je -CONH2 (ovdje identificirani kao spojevi redom 16b1, 16b2 i 16b3).
(viii) each R1 linked to the carbon atoms at positions 3 and 5 of the piperidine ring is independently —ONO2; and R1 linked to the carbon atom at position 4 of the piperidine ring is H; 
(viii) svaki od R1 vezan na ugljikove atome u položajima 3 i 5 piperidinskog prstena je skupina donor dušikovog monoksida -ONO2; i R1 vezan na ugljikov atom u položaju 4 piperidinskog prstena je H (ovdje identificirani kao spojevi redom 6b1, 6b2 i 6b3);
(xiii) each R1 linked to the carbon atoms at positions 3, 4 and 6 of the azepane ring is independently —CH2—ONO2; and R1 linked to the carbon atom at position 5 of the azepane ring is H; 
svaki od R1 vezan na ugljikove atome u položajima 3, 4 i 6 azepanskog prstena je skupina donor dušikovog monoksida -ONO2; i R1 vezan na ugljikov atom u položaju 5 azepanskog prstena je H (ovdje identificirani kao spojevi redom 14b1, 14b2 i 14b3);
extracting, from a bitstream, encoded image data of a current picture assigned to a maximum coding unit of the current picture; 
ekstrahiranje, iz toka bitova, kodiranih podataka slike trenutne slike dodijeljene maksimalnoj jedinici kodiranja trenutne slike;
extracting, from the bitstream, information about a coded depth for the maximum coding unit wherein the information about the coded depth comprises split information of a current coding unit, the maximum coding unit is hierarchically split into coding units of at least one depth according to the split information which is a flag indicating whether the current coding unit of a current depth, among the coding units, is split into coding units of a lower depth; 
ekstrahiranje, iz toka bitova, informacija o dubini kodiranja za maksimalnu jedinicu kodiranja, pri čemu informacije o dubini kodiranja obuhvaćaju podijeljenu informaciju o trenutnoj jedinici za kodiranje, maksimalna jedinici za kodiranje je hijerarhijski podijeljena u kodirajuće jedinice najmanje jedne dubine u skladu s podijeljenom informacijom koja je indikator koji označava da li je trenutna jedinica za kodiranje trenutne dubine, između jedinica za kodiranje, podijeljena u jedinice za kodiranje niže dubine;
A humanized monoclonal antibody having a heavy chain and a light chain comprising the amino acid sequences of SEQ ID NO:35 and SEQ ID NO:31, respectively. 
Humanizirano protutijelo, naznačeno time što ima teški lanac i laki lanac, koji imaju aminokiselinske sljedove SEQ ID NO:35 odnosno SEQ ID NO:31.
The antibody of claim 5, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), psoriasis, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease and systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis/Graves disease, pernicious anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type 1-diabetes mellitus, Good pasture's syndrome, myasthenia gravis, autoimmune haemolytic anaemia, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs Ag negative), cryptogenic cirrhosis, Sjogren's syndrome, dermatomyositis, scleroderma, mixed tissues connective disease, discoid lupus erythematosus, and systemic vasculitis. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 3, naznačeno time što se autoimunu ili upalnu bolest bira iz skupine koju čine reumatoidni artritis, multipla skleroza, proliferativni lupus s glomerulonefritisom, upalna bolest crijeva (IBD), psorijaza, idiopatska trombocitopenična purpura (ITP), Crohnova bolest i sistemni eritematozni lupus (SLE), Hashimotoov tireoiditis, primarni miksoedem, tirotoksikoza/Gravesova bolest, perniciozna anemija, autoimuni atrofični gastritis, autoimuni karditis, Addisonova bolest, prijevremena menopauza, dijabetes melitus tip 1, Goodpastureov sindrom, mijastenija gravis, autoimuna hemolitična anemija, idiopatska leukopenija, primarna bilijarna ciroza, aktivni kronični hepatitis (HBs Ag negativni), kriptogena ciroza, Sjögrenov sindrom, dermatomiozitis, skleroderma, miješana bolest vezivnih tkiva, diskoidni eritematozni lupus, te sistemni vaskulitis.
The compound for use according to claim 3 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Formulacija u skladu sa patentnim zahtjevom 7 gdje je najmanje jedan od dodatnih spojeva odabran od interleukina 2, interleukina 6, interleukina 12, spoj koji poboljšava razvoj odgovora tipa 1 pomoćnih T stanica, interferirajuće RNK, antisens RNK, imikvimoda, ribavirina, inhibitor inozin 5'-monofosfat dehidrogenaze, amantadina, i rimantadina.
A pharmaceutical composition for use in a method of therapy, comprising an antibody which binds to the extracellular portion of a tumor-associated antigen, said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: 
Farmaceutski pripravak za primjenu u postupku liječenja, koja se sastoji od antitijela koje se veže za ekstracelularni dio antigena povezanog s tumorom, Navedeni s tumorom povezani antigen koji ima sekvencu koju kodira nukleinska kiselina koja se odabire iz skupine sastavljene od:
The pharmaceutical composition for use as claimed in claim 1, wherein the method of therapy is a method of treatment or prevention of a cancer characterized by expression of the tumor-associated antigen according to claim 1, in which the cancer is preferably an esophageal tumor, an ovarian tumor, a head-neck tumor, a kidney tumor, a liver tumor, a lung tumor, a breast tumor, a prostate tumor, a colon tumor, a gastric tumor, a stomach cancer, a pancreatic tumor, a renal cell carcinoma, a colon carcinoma or a mammary carcinoma. 
Farmaceutski pripravak za primjenu sukladno zahtjevu 1, pri čemu je postupak terapije postupak liječenja ili prevencije karcinoma, naznačena ekspresijom antigena povezanog tumora sukladno zahtjevu 1, pri čemu je karcinom poželjno tumor jednjaka, tumor jajnika, tumor glave-vrata, tumor bubrega, tumor jetre, tumor pluća, tumor dojke, tumor prostate, tumor debelog crijeva, tumor želuca, karcinom želuca, tumor pankreasa, karcinom bubrežnih stanica, karcinom debelog crijeva ili karcinom dojke.
The pharmaceutical composition for use as claimed in claim 1 or 2, in which the tumor-associated antigen comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 58, 59, 60, 68 and 69. 
Farmaceutski pripravak radi primjene sukladno zahtjevu 1 ili 2, pri čemu antigen povezan s tumorom ima aminokiselinsku sekvencu odabranu iz skupine sastavljene od SEQ ID NO: 2, 58, 59, 60, 68 i 69.
The pharmaceutical composition for use as claimed in any of claims 1 to 5, which is in the form of a vaccine. 
Farmaceutski pripravak radi primjene sukladno bilo kojem od zahtjeva 1 do 5, što je u obliku cjepiva.
The humanized bispecific antibody for use according to claim 10, wherein the disease is selected from the group consisting of an allergic disease, asthma, cancer, an autoimmune disease, scleroderma and idiopathic pulmonary fibrosis. 
Humanizirano bispecifično protutijelo za uporabu prema zahtjevu 10, naznačeno time da je bolest odabrana iz skupine koju čine alergijska bolest, astma, rak, autoimuna bolest, skleroderma i idiopatska plućna fibroza.
Use of the humanized bispecific antibody of any one of the claims 1 to 4 in research applications, wherein said antibody comprises a label such as a radiolabel, a fluorophore, a chromophore, an imaging agent or a metal ion. 
Uporaba humaniziranog bispecifičnog protutijela iz bilo kojeg od patentnih zahtjeva 1 do 4 za istraživačke primjene, naznačena time da navedeno protutijelo sadrži oznaku kao što je radioaktivna oznaka, fluorofor, kromofor, sredstvo za snimanje ili metalni ion.
is an optionally substituted phenyl or naphthyl ring; 
je po izboru supstituiran fenil ili naftil prsten;
The antifouling paint according to claim 1 or 2, wherein the conventional biocides are selected from the group consisting of zinc pyrithione, copper pyrithione, zinc ethylene bis dithiocarbamate, tolylfluanide, dichlofluanide, 4,5-dichloro-2-N-octyl-4-isothiazoline-3-one, N'-tert-butyl-N-cyclopropyl-6-(methylthio)-1,3,5-triazine-2,4-diamine, and any combination thereof. 
Protuobraštajni premaz prema zahtjevu 1 ili 2, naznačeno time da su konvencionalni biocidi izabrani među grupom koja se sastoji od cinkovog piritiona, bakrovog piritiona, cinkovog etilena bis ditiokarbamata, tolilfluanida, diklo-fluanida, 4,5-diklor-2-oktil-2H-izotiazol-3-ona, N'-tert-butil-N-ciklopropil-6-(metiltio)-1,3,5,-triazin-2,4-diamina, te svake kombinacije istih.
A geocell (10) formed from polymeric strips (14), characterized by at least one modified polymeric strip (14) having a storage modulus of 500 MPa or greater when measured in the machine direction by Dynamic Mechanical Analysis (DMA) according to ASTM D4065 at 23°C and at a frequency of 1 Hz. 
Geoćelija (10) načinjena od polimernih traka (14), naznačena time da barem jedna modificirana polimerna traka (14) ima modul pohrane od 500 MPa ili veći kada se mjeri u smjeru obrade pomoću dinamičke mehaničke analize (DMA) prema ASTM D4065 na 23°C i na frekvenciji od 1 Hz.
The geocell (10) of claim 1, the at least one polymeric strip (14) having a storage modulus of 150 MPa or greater when measured in the machine direction by Dynamic Mechanical Analysis (DMA) according to ASTM D4065 at 63°C and at a frequency of 1 Hz. 
Geoćelija (10) prema zahtjevu 1, te barem jedna polimerna traka (14) ima modul pohrane od 150 MPa ili veći kada se mjeri u smjeru obrade pomoću dinamičke mehaničke analize (DMA) prema ASTM D4065 na 63°C i na frekvenciji od 1 Hz.
The geocell (10) of claim 1, the at least one polymeric strip (14) having a long term design stress of 2.6 MPa or greater, when measured according to the PRS SIM procedure. 
Geoćelija (10) prema zahtjevu 1, te barem jedna polimerna traka (14) ima dugotrajno konstrukcijsko naprezanje od 2.6 MPa ili više, kada se mjeri prema PRS SIM postupku.
The geocell (10) of claim 1, 2 or 3, wherein the at least one polymeric strip (14) has a stress at 12% strain of 14.5 MPa or greater when measured according to the Izhar procedure at 23°C. 
Geoćelija (10) prema zahtjevu 1, 2 ili 3, naznačena time da barem jedna polimerna traka (14) ima kod 12% istezanja naprezanje od 14.5 MPa ili veće kada se mjeri prema Izharovom postupku na 23°C.
The geocell (10) of claim 1, 2 or 3, wherein the at least one polymeric strip has a coefficient of thermal expansion of 120 x 10-6 /°C or less at 25°C according to ASTM D696. 
Geoćelija (10) prema zahtjevu 1, 2 ili 3, naznačena time da barem jedna polimerna traka ima koeficijent toplinskog rastezanja od 120 x 10-6 /°C ili manje na 25°C prema ASTM D696.
Arrangement according to Claim 1, characterized in that the front penetrator parts (10) are configured as solid bodies in hard metal. 
Raspored prema zahtjevu 1, naznačen time da su prednji dijelovi penetratora (10) konfigurirani kao čvrsta tijela od tvrdog metala.
Arrangement according to Claim 1, characterized in that the rear fin parts (9, 9') are configured with triangular cross section, corresponding to the tubular shape of the front penetrator part (10). 
Raspored prema zahtjevu 1, naznačen time da su stražnji dijelovi stabilizatora (9, 9') konfigurirani s trokutastim presjekom, koji odgovara cjevastom obliku prednjeg dijela penetratora (10).
represents a hydrogen atom, a methyl group, or an ethyl group; 
predstavlja atom vodika, metilnu skupinu ili etilnu skupinu;
represents a hydrogen atom or a fluorine atom; 
predstavlja atom vodika ili atom fluora;
A combination as claimed in claim 18, or a combination for use as claimed in claim 19, wherein an inhibitor of TGFβ synthesis, for example pirfenidone, is the other pharmaceutically active agent. 
Kombinacija u skladu s patentnim zahtjevom 18, ili kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 19, naznačena time što je inhibitor sinteze TGFβ, primjerice pirfenidon, drugo farmaceutski aktivno sredstvo.
A combination as claimed in claim 18, or a combination for use as claimed in claim 19, wherein an anti avβ6 antibody is the other pharmaceutically active agent. 
Kombinacija u skladu s patentnim zahtjevom 18, ili kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 19, naznačena time što je protutijelo protiv avβ6 drugo farmaceutski aktivno sredstvo.
represents a hydrogen atom, a methyl group or an ethyl group; and 
predstavlja atom vodika, metilnu skupinu ili etilnu skupinu; i
A humanized antibody having a heavy chain and a light chain comprising the amino acid sequences of SEQ ID NO:35 and SEQ ID NO:31, respectively. 
Humanizirano protutijelo, naznačeno time što ima teški lanac i laki lanac, koji imaju aminokiselinske sljedove SEQ ID NO:35 odnosno SEQ ID NO:31.
The antibody for use according to claim 2, wherein the disease or disorder is selected from the group consisting of: graft v. host disease, autoimmune or inflammatory disease, and CD40-expressing cancer. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 2, naznačeno time što se bolest ili poremećaj bira iz skupine koju čine: reakcija presatka prema domaćinu, autoimuna ili upalna bolest, te rak koji eksprimira CD40.
The antibody for use according to claim 3, wherein the autoimmune or inflammatory disease is selected from the group consisting of rheumatoid arthritis, multiple sclerosis, proliferative lupus glomerulonephritis, inflammatory bowel disease (IBD), psoriasis, idiopathic thrombocytopenic purpura (ITP), Crohn's Disease and systemic lupus erythematosus (SLE), Hashimoto's thyroiditis, primary myxoedema, thyrotoxicosis/Graves disease, pernicious anaemia, autoimmune atrophic gastritis, autoimmune carditis, Addison's disease, premature menopause, type 1-diabetes mellitus, Good pasture's syndrome, myasthenia gravis, autoimmune haemolytic anaemia, idiopathic leucopenia, primary biliary cirrhosis, active chronic hepatitis (HBs Ag negative), cryptogenic cirrhosis, Sjogren's syndrome, dermatomyositis, scleroderma, mixed tissues connective disease, discoid lupus erythematosus, and systemic vasculitis. 
Protutijelo namijenjeno upotrebi u skladu s patentnim zahtjevom 3, naznačeno time što se autoimunu ili upalnu bolest bira iz skupine koju čine reumatoidni artritis, multipla skleroza, proliferativni lupus s glomerulonefritisom, upalna bolest crijeva (IBD), psorijaza, idiopatska trombocitopenična purpura (ITP), Crohnova bolest i sistemni eritematozni lupus (SLE), Hashimotoov tireoiditis, primarni miksoedem, tirotoksikoza/Gravesova bolest, perniciozna anemija, autoimuni atrofični gastritis, autoimuni karditis, Addisonova bolest, prijevremena menopauza, dijabetes melitus tip 1, Goodpastureov sindrom, mijastenija gravis, autoimuna hemolitična anemija, idiopatska leukopenija, primarna bilijarna ciroza, aktivni kronični hepatitis (HBs Ag negativni), kriptogena ciroza, Sjögrenov sindrom, dermatomiozitis, skleroderma, miješana bolest vezivnih tkiva, diskoidni eritematozni lupus, te sistemni vaskulitis.
The antibody for use according to any one of claims 2-5, wherein said antibody is administered by a parenteral route, intravenous route or subcutaneous route of administration. 
Protutijelo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 2-5, naznačeno time što se navedeno protutijelo primjenjuje parenteralnim načinom, intravenskim načinom ili supkutanim načinom primjene.
obtaining a plant or plant matter comprising apoplast-localized VLPs, apoplast-localized proteins, or protein suprastructures; wherein the plant matter consist of entire plants, plant leaves, stems, fruit, roots or a combination thereof; 
dobivanje biljke ili biljne tvari koja sadrži Apoplast-lokalizirane proteine, ili proteine suprastrukture; pri čemu se biljna tvar sastoji od cjelovitih biljaka, biljnih listova, stabljike, voća, korjena ili njihove kombinacije;
The method of claim 7, wherein the nucleic acid is introduced into the plant in a transient manner, or, the nucleic acid is stably integrated within a genome of the plant. 
Postupak sukladno patentnom zahtjevu 1, naznačen time, da se nukleinska kiselina uvodi u biljku na prijelazni način ili gdje je nukleinska kiselina stabilno integrirana unutar genoma biljke.
The method of claim 13, wherein, in the case of preparing plant derived virus-like particles (VLPs), the step of purifying comprises filtering the apoplast fraction using depth filtration to produce the filtered fraction, followed by chromatography of the filtered fraction using size exclusion chromatography, cation exchange resin or affinity chromatography, or a combination thereof; or wherein, in the case of preparing plant derived proteins, or protein suprastructures, the step of purifying comprises filtering the apoplast fraction using depth filtration to produce a clarified extract, followed by chromatography of the clarified extract using size exclusion chromatography, cation exchange resin or affinity chromatography, or a combination thereof. 
Postupak sukladno patentnom zahtjevu 4, naznačen time, da nadalje obuhvaća korak d) odjeljivanja proteina ili suprastrukturnih proteina, u filtriranoj frakciji iz staničnog krhotina i netopivih materijala ili d) pročišćavanja biljnih proteina ili suprastrukturnih proteina iz filtrirane frakcije. Postupak sukladno patentnom zahtjevu 13, naznačen time, što se korak odvajanja provodi centrifugiranjem ili pri čemu se korak odvajanja provodi dubinskom filtracijom. Postupak sukladno patentnom zahtjevu 9 ili 13, naznačen time, da korak pročišćavanja obuhvaća filtriranje frakcije filtriranjem dubine da se dobije pročišćeni ekstrakt, nakon čega slijedi kromatografija pročišćenog ekstrakta upotrebom kromatografije isključenja veličine, kationske izmjenjivačke smole ili afinitetne kromatografije ili njihove kombinacije.
dissolving noradrenaline and the excipient in deoxygenated or degassed water, to obtain a concentration of noradrenaline from 0.04 to 0.20 mg/ml, 
otapanje noradrenalina i izborno ekscipijenasa u deoksigeniziranoj ili otplinjenoj vodi, da bi se dobila koncentracija noradrenalina od 0.04 do 0.20 mg/ml,
adjusting the pH of the resulting solution by adding hydrochloric acid until a value in the range from 3.2 to 3.6 is achieved, 
podešavanje pH rezultirajuće otopine dodavanjem klorovodične kiseline sve dok se ne postigne vrijednost u opsegu od 3.2 do 3.6,
filtrating the resulting noradrenaline solution in an inert gas current, 
filtracija rezultirajuće otopine noradrenalina u struji inertnog plina,
distributing the noradrenaline solution in an inert gas current, 
raspodjela otopine noradrenalina u struji inertnog plina,
represents a hydrogen atom or a fluorine atom; and 
predstavlja atom vodika ili atom fluora;
represents a hydrogen atom, a methyl group, or an ethyl group; 
predstavlja atom vodika, metilnu skupinu ili etilnu skupinu; i
wherein the dry matter comprises: 
u kojoj suha tvar sadrži:
Pharmaceutical combination for use according to claim 1, wherein the pharmaceutical combination is for use in a method of treatment of malignant pleural mesothelioma. 
Farmaceutska kombinacija za uporabu prema zahtjevu 1, naznačena time, da se farmaceutska kombinacija upotrebljava u postupku liječenja malignog pleuralnog mezotelioma.
The compound for use according to claim 8 wherein the compound is for use in a method of treatment of malignant pleural mesothelioma. 
Spoj za uporabu prema zahtjevu 8, naznačen time, da se spoj upotrebljava u postupku liječenja malignog pleuralnog mezotelioma.
The compound for use according to claim 8 or 9, wherein the pharmaceutically acceptable salt of the compound N -[4-[2-(2-amino-4,7-dihydro-4-oxo-1 H -pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-L-Glutamic acid is its disodium salt. 
Spoj za uporabu prema zahtjevu 8 ili 9, naznačen time, da farmaceutski prihvatljiva soli spoja N-[4-[2-(2-amino-4,7-dihidro-4-okso-1H-pirolo[2,3-d]pirimidin-5-il)etil]benzoil]-L-glutaminske kiseline, predstavlja njegovu dinatrijevu sol.
A method as claimed in Claim 14, wherein the third polymeric material is a non-ionic polymer and the pH of the inner coating preparation is adjusted prior to coating to be at least 0.5 pH units higher than the pH threshold of the second polymeric material. 
Postupak u skladu s patentnim zahtjevom 11, naznačeno time, da je navedeni treći polimerni materijal je spomenuti neionski polimer, pH unutarnjeg pripravka za prevlačenje se namješta prije premazivanja da bude najmanje 0,5 pH jedinica veći od pH praga drugog polimernog materijala.
A composition comprising desmopressin for use in the treatment of nocturia or nocturnal polyurea to reduce the number of nocturnal voids in a male patient in need thereof, the composition comprising an orodispersible dose of desmopressin of 25 µg or 50 µg, wherein the dose is measured as the free base of desmopressin, for administration prior to bedtime. 
Pripravak, koji sadrži dezmopresin za uporabu kod liječenja muškog pacijenta koji ima nokturiju ili noćnu poliuriju, za smanjenje broja noćnih pražnjenja mjehura kod muškog pacijenta, koji treba takvo liječenje, te pripravak sadrži orodisperzibilnu dozu dezmopresina od 25 µg, naznačen time da se doza mjeri kao slobodna baza dezmopresina, za administraciju prije počinka.